局部钙调神经磷酸酶抑制剂治疗白癜风的疗效:系统综述与荟萃分析
该系统综述与荟萃分析纳入56项研究,评估局部钙调神经磷酸酶抑制剂(TCI)单用或联合光疗治疗白癜风的复色反应。TCI单用中位治疗3个月时,至少轻度复色率达55.0%,至少中度复色率38.5%,显著复色率18.1%;联合光疗时至少轻度复色率89.5%,显著复色率47.5%。结论鼓励TCI单用或联合光疗用于白癜风患者。
要点
- TCI单用治疗3个月,55.0%患者达至少轻度复色,18.1%达显著复色。
- TCI联合光疗显著提高复色率,至少轻度复色达89.5%。
- 面颈部病变对TCI单用反应较好,至少轻度复色率73.1%。
核心结论
- TCI单用或联合光疗均应被鼓励用于白癜风患者。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Web of Science和Cochrane Library至2018年8月6日。
- 共纳入56项研究,其中46项(1499例患者)用于评估治疗反应。
- 采用随机效应荟萃分析,使用通用逆方差加权法。
主要发现
- TCI单用中位治疗3个月(范围2-7个月),至少轻度复色率55.0%(95%CI 42.2%-67.8%),至少中度复色率38.5%(95%CI 28.2%-48.8%),显著复色率18.1%(95%CI 13.2%-23.1%)。
- 亚组分析中,面颈部病变至少轻度复色率73.1%(95%CI 32.6%-83.5%),显著复色率35.4%(95%CI 24.9%-46.0%)。
- TCI联合光疗至少轻度复色率89.5%(95%CI 81.1%-97.9%),显著复色率47.5%(95%CI 30.6%-64.4%)。
关键数值与推荐
- 主要结局为至少轻度(≥25%)、至少中度(≥50%)和显著(≥75%)复色反应率。
- 复色率计算为单个研究中显示相应复色的参与者数除以完成该研究的参与者总数。
临床怎么用
- 临床可鼓励使用TCI单用或联合光疗治疗白癜风。
- 面颈部病变可优先考虑TCI单用治疗。
- 联合光疗可提高复色反应率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Topical calcineurin inhibitors (TCIs), including tacrolimus and pimecrolimus, have been widely used for the treatment of vitiligo; however, the efficacy of TCI monotherapy is often underestimated. OBJECTIVES: To estimate the treatment responses to both TCI monotherapy and TCI accompanied by phototherapy for vitiligo, based on relevant prospective studies, and to systematically review the mechanism of action of TCIs for vitiligo treatment. DATA SOURCES: A comprehensive search of the MEDLINE, Embase, Web of Science and Cochrane Library databases from the date of database inception to August 6, 2018, was conducted. The main key words used were vitiligo, topical calcineurin inhibitor, tacrolimus, pimecrolimus, and FK506. STUDY SELECTION: Of 250 studies initially identified, the full texts of 102 articles were assessed for eligibility. A total of 56 studies were identified: 11 studies on the TCI mechanism, 36 studies on TCI monotherapy, 12 studies on TCI plus phototherapy, and 1 study on TCI maintenance therapy. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data on study design, patients, intervention characteristics, and outcomes. Random-effects meta-analyses using the generic inverse variance weighting were performed for the TCI monotherapy and TCI plus phototherapy groups. MAIN OUTCOMES AND MEASURES: The primary outcomes were the rates of at least mild (≥25%), at least moderate (≥50%), and marked (≥75%) repigmentation responses to treatment. These rates were calculated by dividing the number of participants in an individual study who showed the corresponding repigmentation by the total number of participants who completed that study. RESULTS: In the 56 studies included in the analysis, 46 (1499 patients) were selected to evaluate treatment response. For TCI monotherapy, an at least mild response was achieved in 55.0% (95% CI, 42.2%-67.8%) of 560 patients in 21 studies, an at least moderate response in 38.5% (95% CI, 28.2%-48.8%) of 619 patients in 23 studies, and a marked response in 18.1% (95% CI, 13.2%-23.1%) of 520 patients in 19 studies after median treatment duration of 3 months (range, 2-7 months). In the subgroup analyses, face and neck lesions showed an at least mild response in 73.1% (95% CI, 32.6-83.5%) of patients, and a marked response in 35.4% (95% CI, 24.9-46.0%) of patients. For TCI plus phototherapy, an at least mild response to TCI plus phototherapy was achieved in 89.5% (95% CI, 81.1-97.9%) of patients, and a marked response was achieved in 47.5% (95% CI, 30.6-64.4%) of patients. CONCLUSIONS AND RELEVANCE: The use of TCIs, both as a monotherapy and in combination with phototherapy, should be encouraged in patients with vitiligo.
引用
- Lee JH, Kwon HS, Jung HM, et al. Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019. PMID: 31141108. doi:10.1001/jamadermatol.2019.0696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。